menu
    • menu
    [{"orgOrder":0,"company":"PAREXEL International Corporation","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rilvegostomig","moa":"PDCD1","graph1":"Oncology","graph2":"Phase I","graph3":"PAREXEL International Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PAREXEL International Corporation \/ PAREXEL International Corporation","highestDevelopmentStatusID":"6","companyTruncated":"PAREXEL International Corporation \/ PAREXEL International Corporation"},{"orgOrder":0,"company":"PAREXEL International Corporation","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AZD0516","moa":"STEAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PAREXEL International Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PAREXEL International Corporation \/ PAREXEL International Corporation","highestDevelopmentStatusID":"7","companyTruncated":"PAREXEL International Corporation \/ PAREXEL International Corporation"},{"orgOrder":0,"company":"PAREXEL International Corporation","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"PCSK9","graph1":"Endocrinology","graph2":"Phase I","graph3":"PAREXEL International Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PAREXEL International Corporation \/ PAREXEL International Corporation","highestDevelopmentStatusID":"6","companyTruncated":"PAREXEL International Corporation \/ PAREXEL International Corporation"},{"orgOrder":0,"company":"PAREXEL International Corporation","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Polyethylene Glycol 3350","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"PAREXEL International Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"PAREXEL International Corporation \/ PAREXEL International Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PAREXEL International Corporation \/ PAREXEL International Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by PAREXEL International Corporation

    Menu

    PAREXEL International Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PAREXEL International Corporation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PAREXEL International Corporation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyethylene Glycol 3350

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Recipient : Norgine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PLENVU vs Sodium Picosulfate for Bowel Cleansing in Children

                            Details : Plenvu (Polyethylene Glycol 3350) is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Gastrointestinal Diseases.

                            Product Name : Plenvu

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2025

                            Lead Product(s) : Polyethylene Glycol 3350

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Recipient : Norgine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PAREXEL International Corporation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PAREXEL International Corporation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Laroprovstat

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18...

                            Details : Laroprovstat is a Miscellaneous drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 14, 2025

                            Lead Product(s) : Laroprovstat

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PAREXEL International Corporation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PAREXEL International Corporation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD0516

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

                            Details : AZD0516 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            September 18, 2025

                            Lead Product(s) : AZD0516

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PAREXEL International Corporation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PAREXEL International Corporation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rilvegostomig

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants Wit...

                            Details : Rilvegostomig is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 08, 2025

                            Lead Product(s) : Rilvegostomig

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth